Huadong Pharmaceutical Company
Huadong Pharmaceutical Company, also known as Huadong Medicine Co., Ltd., is a prominent player in the pharmaceutical industry, headquartered in China (CN). Established in 1996, the company has made significant strides in the development and production of innovative medicines, primarily focusing on oncology, cardiovascular, and central nervous system disorders. With a strong operational presence across various regions in China and expanding internationally, Huadong Pharmaceutical is renowned for its commitment to quality and research-driven solutions. The company’s core products include a range of generic and proprietary drugs, distinguished by their efficacy and safety profiles. Recognised for its robust market position, Huadong has achieved notable milestones, including numerous certifications and partnerships that enhance its global reach. As a leader in the pharmaceutical sector, Huadong Pharmaceutical continues to contribute to healthcare advancements, ensuring better patient outcomes worldwide.
DitchCarbon Score
How does Huadong Pharmaceutical Company's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Huadong Pharmaceutical Company's score of 9 is lower than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Huadong Pharmaceutical Company's reported carbon emissions
In 2023, Huadong Pharmaceutical Company reported carbon emissions of approximately 14,288,850 kg CO2e from Scope 1 sources, contributing to a total of about 152,103,450 kg CO2e for both Scope 1 and Scope 2 emissions. This marks an increase from 2022, where Scope 1 emissions were about 11,305,600 kg CO2e, with a total of approximately 108,596,090 kg CO2e for Scope 1 and Scope 2 combined. Despite the rise in emissions, there are currently no publicly disclosed reduction targets or climate pledges from Huadong Pharmaceutical. The company has not provided data on Scope 3 emissions, which typically encompass indirect emissions from the supply chain and product use. As the pharmaceutical industry increasingly focuses on sustainability, Huadong's commitment to addressing climate change remains unclear, highlighting a potential area for future improvement and transparency.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 11,305,600 | 00,000,000 |
| Scope 2 | - | - |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Huadong Pharmaceutical Company is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
